Cargando…

Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells

Epigenetic anticancer drugs such as histone deacetylase (HDAC) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects. In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fl...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Kouji, Hakata, Shuko, Terashima, Jun, Gamou, Toshie, Habano, Wataru, Ozawa, Shogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022900/
https://www.ncbi.nlm.nih.gov/pubmed/27509880
http://dx.doi.org/10.3892/or.2016.5008
_version_ 1782453597088251904
author Okada, Kouji
Hakata, Shuko
Terashima, Jun
Gamou, Toshie
Habano, Wataru
Ozawa, Shogo
author_facet Okada, Kouji
Hakata, Shuko
Terashima, Jun
Gamou, Toshie
Habano, Wataru
Ozawa, Shogo
author_sort Okada, Kouji
collection PubMed
description Epigenetic anticancer drugs such as histone deacetylase (HDAC) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects. In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability. Exposure to a combination of 5-FU (1.75 µM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7. Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation. These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex (MHC) class (GO:0002504) and MHC protein complex (GO:0042611). Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes. Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide. These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5-FU. To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
format Online
Article
Text
id pubmed-5022900
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-50229002016-09-22 Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells Okada, Kouji Hakata, Shuko Terashima, Jun Gamou, Toshie Habano, Wataru Ozawa, Shogo Oncol Rep Articles Epigenetic anticancer drugs such as histone deacetylase (HDAC) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects. In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability. Exposure to a combination of 5-FU (1.75 µM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7. Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation. These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex (MHC) class (GO:0002504) and MHC protein complex (GO:0042611). Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes. Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide. These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5-FU. To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression. D.A. Spandidos 2016-10 2016-08-08 /pmc/articles/PMC5022900/ /pubmed/27509880 http://dx.doi.org/10.3892/or.2016.5008 Text en Copyright: © Okada et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Okada, Kouji
Hakata, Shuko
Terashima, Jun
Gamou, Toshie
Habano, Wataru
Ozawa, Shogo
Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
title Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
title_full Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
title_fullStr Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
title_full_unstemmed Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
title_short Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
title_sort combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class ii and p21 genes and activates caspase-3/7 in human colon cancer hct-116 cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022900/
https://www.ncbi.nlm.nih.gov/pubmed/27509880
http://dx.doi.org/10.3892/or.2016.5008
work_keys_str_mv AT okadakouji combinationofthehistonedeacetylaseinhibitordepsipeptideand5fluorouracilupregulatesmajorhistocompatibilitycomplexclassiiandp21genesandactivatescaspase37inhumancoloncancerhct116cells
AT hakatashuko combinationofthehistonedeacetylaseinhibitordepsipeptideand5fluorouracilupregulatesmajorhistocompatibilitycomplexclassiiandp21genesandactivatescaspase37inhumancoloncancerhct116cells
AT terashimajun combinationofthehistonedeacetylaseinhibitordepsipeptideand5fluorouracilupregulatesmajorhistocompatibilitycomplexclassiiandp21genesandactivatescaspase37inhumancoloncancerhct116cells
AT gamoutoshie combinationofthehistonedeacetylaseinhibitordepsipeptideand5fluorouracilupregulatesmajorhistocompatibilitycomplexclassiiandp21genesandactivatescaspase37inhumancoloncancerhct116cells
AT habanowataru combinationofthehistonedeacetylaseinhibitordepsipeptideand5fluorouracilupregulatesmajorhistocompatibilitycomplexclassiiandp21genesandactivatescaspase37inhumancoloncancerhct116cells
AT ozawashogo combinationofthehistonedeacetylaseinhibitordepsipeptideand5fluorouracilupregulatesmajorhistocompatibilitycomplexclassiiandp21genesandactivatescaspase37inhumancoloncancerhct116cells